Diabetic kidney disease: challenges, progress, and possibilities - Alicic, R. Z.; Rooney, M. T.; Tuttle, K. R. (Clin J Am Soc Nephrol, 2017)

UK Renal Registry 19th annual report: chapter 12 multisite dialysis access audit in England, Northern Ireland and Wales in 2015 and 2014 PD one year follow-up: national and centre-specific analyses - Hole, B. (Nephron, 2017)

Changes in diabetes-related complications in the United States - Gregg, E. W.; Williams, D. E.; Geiss, L. (N Engl J Med, 2014)

A decade after the KDOQI CKD guidelines: impact on the National Kidney Foundation - Vassalotti, J. A.; Piraino, B.; Szczech, L. A. (Am J Kidney Dis, 2012)

The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy - Mogensen, C. E.; Christensen, C. K.; Vittinghus, E. (Diabetes, 1983)

Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74 - Retnakaran, R. (Diabetes, 2006)

Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria - Gaede, P. (Nephrol Dial Transplant, 2004)

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes - Drucker, D. J.; Nauck, M. A. (Lancet, 2006)

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody - Pyke, C. (Endocrinology, 2014)

Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells - Schlatter, P. (Regul Pept, 2007)

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes - Muskiet, M. H. A. (Nat Rev Nephrol, 2017)

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus - Tonneijck, L. (Am J Physiol Ren Physiol, 2019)

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial - Tonneijck, L. (Diabetologia, 2016)

Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial - Skov, J. (Diabetes Obes Metab, 2016)

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats - Zhou, X. (Cardiovasc Diabetol, 2015)

The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential - Fujita, H. (Kidney Int, 2014)

Glucagon-like peptide 1 and its cleavage products are renoprotective in murine diabetic nephropathy - Moellmann, J. (Diabetes, 2018)

FDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diabetes-mellitus-developing-drugs-and-therapeuticbiologics-treatment-and-prevention. Accessed 3 Oct 2019.

Lixisenatide in patients with type 2 diabetes and acute coronary syndrome - Pfeffer, M. A. (N Engl J Med, 2015)

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial - Muskiet, M. H. A. (Lancet Diabetes Endocrinol, 2018)

Liraglutide and cardiovascular outcomes in type 2 diabetes - Marso, S. P. (N Engl J Med, 2016)

Liraglutide and renal outcomes in type 2 diabetes - Mann, J. F. E. (N Engl J Med, 2017)

Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial - Davies, M. J. (Diabetes Care, 2016)

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes - Marso, S. P. (N Engl J Med, 2016)

Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes - Holman, R. R. (N Engl J Med, 2017)

Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial - Bethel, M. A. (Diabetes Care, 2020)

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial - Hernandez, A. F. (Lancet, 2018)

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial - Tuttle, K. R. (Lancet Diabetes Endocrinol, 2018)

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - Gerstein, H. C. (Lancet, 2019)

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial - Gerstein, H. C. (Lancet, 2019)

Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists - Dubois-Laforgue, D. (Diabetes Res Clin Pract, 2014)

Acute interstitial nephritis after treatment with liraglutide - Gariani, K.; Seigneux, S.; Moll, S. (Am J Kidney Dis, 2014)

Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction - Chen, Y. T. (J Transl Med, 2013)

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men - Gutzwiller, J. P. (J Clin Endocrinol Metab, 2004)

GLP-1 agonist associated acute kidney injury: a case report and review - Sharma, T.; Paixao, R.; Villabona, C. (Diabetes Metab, 2019)

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials - Kristensen, S. L. (Lancet Diabetes Endocrinol, 2019)

A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW). 2019. https://clinicaltrials.gov/ct2/show/NCT03819153. Accessed 23 Oct 2019.

Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME(R) trial - Perkovic, V. (Nephrol Dial Transplant., 2019)